Pharmaceutical solution comprising dopamine for use in treating parkinson's disease

Abstract

The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.

1 . A pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration. 
     
     
         2 . The pharmaceutical solution for use according to  claim 1 , wherein dopamine is dopamine hydrochloride. 
     
     
         3 . The pharmaceutical solution for use according to  claim 1 , wherein the pharmaceutical solution is free of preservative agent. 
     
     
         4 . The pharmaceutical composition for use according to  claim 1 , wherein said solution is adapted to be administered into brain ventricle, preferably into right lateral ventricle, preferably close to the interventricular foramen. 
     
     
         5 . The pharmaceutical solution for use according to  claim 1 , wherein said solution is adapted to be administered with an anaerobical pump. 
     
     
         6 . The pharmaceutical solution for use according to  claim 1 , wherein said solution is continuously administered with doses' variations. 
     
     
         7 . The pharmaceutical solution for use according to  claim 1 , wherein said solution is administered with a predominant diurnal dose or with an exclusive diurnal dose. 
     
     
         8 . The pharmaceutical solution for use according to  claim 1 , wherein said solution is administered with the following dosage regimen:
 a continuous and stable diurnal dose,   a bolus administered on morning, and   optionally, at least a bolus when required, and/or   optionally, a continuous and stable nocturnal dose lower than the diurnal dose, preferably at least 25% lower than the diurnal dose, more preferably at least 50% lower than the diurnal dose, more preferably at least 70% lower than the diurnal dose, more preferably at least 80% lower than the diurnal dose, more preferably at least 90% lower than the diurnal dose.   
     
     
         9 . A pharmaceutical solution comprising dopamine hydrochloride, wherein said dopamine hydrochloride is dissolved in saline solution and the solution has a pH between 5.5 and 7. 
     
     
         10 . The pharmaceutical solution according to  claim 9 , which is free of preservative agent. 
     
     
         11 . The pharmaceutical solution according to  claim 9 , containing less than 5% of oxygen, preferably less than 2% of oxygen, more preferably less than 1% of oxygen, more preferably less than 0.5% of oxygen and more preferably about 0% of oxygen. 
     
     
         12 . The pharmaceutical solution according to  claim 9 , wherein it is in the form of an aqueous solution.